LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$30.48 USD
+1.15 (3.92%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $30.47 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
LENZ Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
LENZ 30.48 +1.15(3.92%)
Will LENZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LENZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LENZ
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?
LENZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect?
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know
Other News for LENZ
Lenz Therapeutics (LENZ) Shares Cross Below 200 DMA
Lenz Therapeutics (LENZ) Target Price Hiked Following FDA Approval
Lenz Therapeutics price target raised by $9 at BofA, here's why
Lenz Therapeutics (LENZ) Sees Raised Price Target After FDA Approval
Lenz Therapeutics price target raised by $8 at H.C. Wainwright, here's why